Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News23 hours agoBrisbane’s new bus timetable sees journey times decrease by two minutes in first three months
-
Noosa News22 hours agoCalls for greater education as growers in WA’s south-west brace for polyphagous shot-hole borer
-
Business22 hours agoWhat it means for shareholders
-
General21 hours agoKim Kardashian not deterred by bar failure